What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.
Our 220-page report provides 160 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market: • Retinal Disorder Drugs • Allergic, Inflammatory & Infective Drugs • Glaucoma Drugs • Dry Eye Drugs • Other Ophthalmic Drugs
The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market: • Novartis • Regeneron • Allergan • Roche • Valeant • Santen • Bayer • Pfizer • Senju • Akorn
The report also includes revenue forecasts to 2026 for the following ophthalmic drugs: • Eylea • Lucentis • Restasis • Lumigan and Ganfort • Travatan/Travatan Z and DuoTrav • Alphagan/Alphagan P and Combigan • Vigamox • Xalatan/Xalacom • Azopt • Jetrea • Hyalein • Cosopt • Tapros/Taflotan • Diquas • Cravit • Alesion • Lotemax
Leading companies and potential for market growth Novartis (including subsidiary Alcon) will remain the leading ophthalmic company to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.
Our work analyses the key companies in the market. See Visiongain’s analysis of over 25 leading companies, including these: • Novartis • Regeneron • Allergan • Roche • Valeant • Santen • Bayer • Pfizer • Senju • Akorn
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Revenue forecasts to 2016 for ophthalmic drugs marketed by the company • Analysis of major products currently on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the ophthalmic drugs industry? Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses: • Highly diverse market needing strong knowledge of key therapeutic indications • Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026 report helps you In summary, our 220-page report gives you the following knowledge: • Revenue forecasts to 2026 for the 10 leading companies in the market – discover the industry’s prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju and Akorn • Revenue forecasts to 2026 for each major submarket – discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs. • Revenue forecasts to 2026 for 17 leading drugs – discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Restasis, Lumigan and Ganfort, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Vigamox, Xalatan/Xalacom, Azopt, Jetrea, Hyalein, Cosopt, Tapros/Taflotan, Diquas, Cravit, Alesion and Lotemax. • Assessment of 21 emerging ophthalmic companies – analysis of products, revenue, mergers & acquisitions and leading pipeline drug candidates • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Ophthalmic Drugs Market Overview 1.2 Global Ophthalmic Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Ophthalmic Drugs 2.1 The Pharmaceutical Industry: a Very Brief Overview 2.2 The Global Burden of Eye Disease 2.3 Ophthalmic Drugs: Market Segmentation 2.4 Glaucoma: the ‘Silent Thief of Sight’ 2.4.1 A Classification of Glaucoma 2.4.1.1 Primary Open-Angle Glaucoma 2.4.1.2 Acute Angle-Closure Glaucoma 2.4.1.3 Congenital Glaucoma 2.4.1.4 Secondary Glaucoma 2.4.1.5 Normal-Tension Glaucoma 2.4.1.6 Ocular Hypertension 2.4.2 Risk Factors for Glaucoma 2.4.3 Diagnosis of Glaucoma 2.4.4 Drug Treatment of Glaucoma 2.4.5 Laser Treatment and Surgery for Glaucoma 2.5 Age-Related Macular Degeneration (AMD) 2.5.1 Dry (non-exudative) AMD 2.5.2 Wet (exudative) AMD 2.5.3 Risk Factors for AMD 2.5.4 Diagnosis of AMD 2.5.5 Treatment of AMD 2.6 Diabetic Retinopathy (DR) 2.6.1 Diagnosis of Diabetic Retinopathy 2.6.2 Treatment of Diabetic Retinopathy 2.7 Ocular Allergy and Allergic Conjunctivitis 2.7.1 Diagnosis of Ocular Allergy 2.7.2 Treatment of Ocular Allergy 2.8 Ocular Inflammatory Disease 2.8.1 Treatment of Ocular Inflammatory Disease 2.9 Eye Infections 2.9.1 Treatment of Eye Infections 2.10 Dry Eye Syndrome 2.10.1 Treatment of Dry Eye Syndrome 2.11 Phases of Clinical Trials 2.12 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2016-2026 3.1 The World Ophthalmic Drugs Market in 2015 3.2 World Ophthalmic Drugs Market: Sales Forecast 2016-2026 3.3 Leading Ophthalmic Drugs 3.4 Leading Companies in the Ophthalmic Drugs Market 3.4.1 Top 25 Ophthalmic Drug Manufacturers 3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2016-2026 3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2016-2026 3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2016-2026 3.5.3 Glaucoma Drugs Market: Sales Forecast 2016-2026 3.5.4 Dry Eye Drugs Market: Sales Forecast 2016-2026 3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2016-2026 3.6 How Will Market Shares Change to 2026? 3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2016-2026 3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers 3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drug Manufacturers 2016-2026 4.1 Allergan Overview 4.1.1 Allergan: Ophthalmic Product Portfolio 4.1.1.1 Restasis: Generic Launch in 2016? 4.1.1.2 Restasis: Sales Forecast 2016-2026 4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries 4.1.1.4 Lumigan and Ganfort: Sales Forecast 2016-2026 4.1.1.5 Refresh Brand Products: the Range 4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle 4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2026 4.1.1.8 Acular: New Forms Receiving FDA Approvals 4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema 4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline 4.1.3 Allergan: Ophthalmic Revenue Forecast 2016-2026 4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2016-2026 4.1.4 Allergan: SWOT Analysis 4.2 Pfizer Overview 4.2.1 Pfizer: Ophthalmic Product Portfolio 4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster 4.2.1.2 Xalatan/Xalacom: Sales Forecast 2016-2026 4.2.2 Pfizer: Ophthalmic Product Pipeline 4.2.3 Pfizer: Revenue Forecast 2016-2026 4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2016-2026 4.2.4 Pfizer: SWOT Analysis 4.3 Regeneron Overview 4.3.1 Regeneron: Ophthalmic Product Portfolio 4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin? 4.3.1.2 Eylea: US Sales Forecast 2016-2026 4.3.2 Regeneron: Ophthalmic Product Pipeline 4.3.3 Regeneron: Revenue Forecast 2016-2026 4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2016-2026 4.3.4 FDA Approves Zaltrap (aflibercept) 4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements 4.3.6 Regeneron: SWOT Analysis 4.4 Akorn Overview 4.4.1 Akorn: Ophthalmic Product Portfolio 4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales 4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck 4.4.2 Akorn: Revenue Forecast 2016-2026 4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2016-2026 4.4.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers 2016-2026 5.1 Bayer Overview 5.1.1 Bayer: Ophthalmic Product Pipeline 5.1.2 Eylea: non-US Sales Forecast 2016-2026 5.1.3 Bayer: Revenue Forecast 2016-2026 5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2016-2026 5.2 Novartis (including Alcon) Overview 5.2.1 Novartis: Ophthalmic Product Portfolio 5.2.1.1 Lucentis: Still a Leading Drug in AMD 5.2.1.2 Lucentis: Non-US Sales Forecast 2016-2026 5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval 5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2026 5.2.1.5 Vigamox: Competes with Alcon’s Moxeza 5.2.1.6 Vigamox: Sales Forecast 2016-2026 5.2.1.7 Azopt: Marketed in Major Markets 5.2.1.8 Azopt: Sales Forecast 2016-2026 5.2.1.9 Jetrea: Sales Revenues Fall Short 5.2.1.10 Jetrea: Non-US Sales Forecast 2016-2026 5.2.2 Novartis: Ophthalmic Product Pipeline 5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis) 5.2.2.2 AKB 9778 (Aerpio Therapeutics) 5.2.3 Novartis: Revenue Forecast 2016-2026 5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2016-2026 5.2.4 Novartis: SWOT Analysis 5.3 Roche Overview 5.3.1 Roche: Ophthalmic Product Portfolio 5.3.1.1 Lucentis: US Sales Forecast 2016-2026 5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales 5.3.1.3 Avastin: Sales Forecast 2016-2026 5.3.2 Roche: Ophthalmic Product Pipeline 5.3.2.1 Lampalizumab (RG7417) 5.3.3 Roche: Revenue Forecast 2016-2026 5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2016-2026 5.3.4 Roche: SWOT Analysis
7. Emerging Ophthalmic Drug Manufacturers in 2016 7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2016 7.2 Acucela 7.3 Aerie Pharmaceuticals 7.4 Aerpio Therapeutics: Developing AKB 9778 7.5 Alimera Sciences 7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales 7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD 7.6 Amakem 7.7 Ampio Pharmaceuticals 7.8 Chengdu Kanghong Pharmaceutical 7.9 Eleven Biotherapeutics 7.10 EyeGate Pharmaceuticals 7.11 Gene Signal 7.11.1 Aganirsen: Preventing Corneal Graft Rejection 7.12 Icon Bioscience 7.13 MacuCLEAR 7.13.1 MC 1101: a Potential Therapy for Dry AMD 7.14 Neurotech 7.15 Omeros 7.16 OphthaliX (Can-Fite BioPharma) 7.17 Ophthotech 7.17.1 Fovista: Potential Game-Changer in AMD 7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials 7.17.3 Zimura: Complement C5 Inhibitor 7.18 Otsuka Pharmaceutical 7.19 pSivida Corp. 7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development? 7.21 Shire 7.21.1 Lifitegrast (SHP606) for Dry Eye 7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity 7.22 ThromboGenics 7.22.1 Jetrea (ocriplasmin) 7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline
8. Qualitative Analysis of the Ophthalmic Drugs Market 2016-2026 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market 8.1.1 Rivalry Among Competitors [Medium] 8.1.2 Threat of New Entrants [Low] 8.1.3 Power of Suppliers [Low] 8.1.4 Power of Buyers [Medium] 8.1.5 Threat of Substitutes [Medium]
9. Conclusions 9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market 9.2 The World Ophthalmic Drugs Market in 2015 9.2.1 Leading Ophthalmic Drugs Market Segments 9.2.2 Leading Ophthalmic Drugs 9.2.3 Leading Ophthalmic Drugs Companies 9.3 World Ophthalmic Drugs Market Forecast 2016-2026 9.4 The Future of the Ophthalmic Drugs Market? 9.4.1 Increasing Revenue Concentration among Specialist Companies 9.4.2 The Rise of Generics 9.4.3 Small Companies Can Have a Big Impact 9.4.4 What Will Succeed in the Ophthalmic Drugs Market?
10. Glossary
Appendix Visiongain’s Bespoke Research Service Some Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Figures Figure 1.1 Global Causes of Visual Impairment (% of cases), 2012 Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015-2026 Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2016 Figure 2.1 Estimated Global Prevalence of Visual Impairment (millions of people), 2010 Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2013 Figure 2.3 Global Causes of Visual Impairment (% of cases), 2013 Figure 2.4 Classification of Glaucoma, 2016 Figure 2.5 Global Causes of Blindness (% of cases), 2013 Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2015 Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015 Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR(%), 2015-2026 Figure 3.4 Top 10 Ophthalmic Drugs: Market Share (%), 2015 Figure 3.5 Top 10 Ophthalmic Drugs: Revenues ($m), 2015 Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2015 Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2015 Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2015-2026 Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2015-2026 Figure 3.10 Glaucoma Drugs Market Forecast: Revenues ($m), 2015-2026 Figure 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), 2015-2026 Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2015-2026 Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015 Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2020 Figure 3.15 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2026 Figure 3.16 World Ophthalmic Drugs Market: Drivers and Restraints, 2016-2026 Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2015-2026 Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2015-2026 Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2015-2026 Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026 Figure 4.5 Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026 Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2015-2026 Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026 Figure 4.8 Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026 Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR(%), 2015-2026 Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 4.11 Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026 Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 4.13 Akorn: Ophthalmic Drugs Market Share (%), 2015-2026 Figure 5.1 Bayer: Eylea Revenue ($m) and AGR(%), 2015-2026 Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 5.3 Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026 Figure 5.4 Novartis: Lucentis Revenue ($m) and AGR(%), 2015-2026 Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR(%), 2015-2026 Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR(%), 2015-2026 Figure 5.7 Novartis: Azopt Revenue ($m) and AGR(%), 2015-2026 Figure 5.8 Novartis: Jetrea Revenue ($m) and AGR(%), 2014-2025 Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 5.10 Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026 Figure 5.11 Roche: Lucentis Revenue ($m) and AGR(%), 2015-2026 Figure 5.12 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2015-2026 Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 5.14 Roche: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026 Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2015 Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2015 Figure 6.3 Santen: Eylea Revenue ($m) and AGR(%), 2015-2026 Figure 6.4 Santen: Hyalein Revenue ($m) and AGR(%), 2015-2026 Figure 6.5 Santen: Cosopt Revenue ($m) and AGR(%), 2015-2026 Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR(%), 2015-2026 Figure 6.7 Santen: Diquas Revenue ($m) and AGR(%), 2015-2026 Figure 6.8 Santen: Cravit Revenue ($m) and AGR(%), 2015-2026 Figure 6.9 Santen: Alesion Revenue ($m) and AGR(%), 2015-2026 Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2015-2026 Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2015-2026 Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2015-2026 Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026 Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2015-2026 Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress, 2016 Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress, 2015 Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress, 2016 Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress, 2016 Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2016-2026 Figure 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026
Actavis Acucela Advanced Vision Research Aerie Pharmaceuticals Aerpio Therapeutics, Inc Alcon Akorn Algeta Alimera Sciences Allergan Allegro Ophthalmics Amakem Ampio Pharmaceuticals Asahi Glass Aton Pharma, Inc. Aventis AYUMI Pharmaceutical Corporation Banyu Pharmaceutical Barr Laboratories Bausch & Lomb Bayer AG Bayer HealthCare Bayer Yakuhin Bristol-Myers Squibb Can-Fite BioPharma Chiron Corporation Chugai Pharmaceutical Ciba-Geigy Ciba Vision Chengdu Kanghong Pharmaceutical Eleven Biotherapeutics Eli Lilly EyeGate Pharmaceuticals Eyetech Inc. Fougera Pharmaceuticals Genentech Gene Signal GSK Hi-Tech Hospira Inc ICN Pharmaceuticals Icon Bioscience Inception Sciences, Inc. InSite Vision Inspire Pharmaceuticals ISTA Pharmaceuticals Jenapharm Kestrel Ophthalmics King Pharmaceuticals Kyorin Pharmaceutical Kyowa Hakko Kirin LEO Pharma MacuCLEAR MacuSight, Inc. MAP Pharmaceuticals MEAgate International FZLLC Meda Medicis Corporation Merck & Co. MerLion MSD K.K. Mystic Pharmaceuticals Nestlé Neurotech Nippon Boehringer Ingelheim Co.,Ltd. NovaBay Pharmaceuticals Novagali Pharma Novartis International AG Novartis Institutes for BioMedical Research Novartis Venture Funds OcuSciences Omeros OphthtaliX Ophthotech Ora, Inc. Otsuka Pharmaceutical Parke-Davis Par Pharmaceutical Pfizer Inc. Pharmacia Philidor PreCision Dermatology Premacure Procter & Gamble pSivida Corp. Quark Pharmaceuticals Regeneron Rekitt Benckiser Roche Consumer Health RXi Pharmaceuticals Salix Sandoz Sanofi Sanofi-Aventis Santaris Pharma Santen Pharmaceutical Co. Santen S.A.S. SARcode Bioscience Schering AG Senju Pharmaceutical Company Ltd. Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. Senju USA Inc. Shire SkinMedica Spark Therapeutics Steigerwald ThromboGenics Upjohn Valeant Pharmaceuticals International Ventana Medical Systems Versant Ventures VersaPharm Warburg Pincus LLC Warner-Lambert Wyeth Pharmaceuticals Zoetis Organisations Mentioned in the Report A*STAR Institute for Infocomm Research (Singapore) American Academy of Ophthalmology (AAO) American Diabetes Association American Society of Retina Specialists (ASRS) Association for Research in Vision and Ophthalmology (ARVO) Emory University European Medicines Agency (EMA) Japanese Ministry of Health, Labour and Welfare (MHLW) Japan Patent Office Johns Hopkins University (Baltimore, US) National Institute of Clinical Excellence (NICE) National Institute of Health (NIH) Ophthalmic Drugs Advisory Committee - Division of the FDA Tokyo University of Science UK National Health Service (NHS) United Nations Department of Economic and Social Affairs, Population Division US Food and Drug Agency (FDA) US National Eye Institute (NEI) US Preventive Services Task Force World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
